Maglin 50 Capsule contains Pregabalin 50mg, an anticonvulsant and neuropathic pain agent primarily indicated for the management of neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia, and spinal cord injury. It is also prescribed as adjunctive therapy for partial-onset seizures in adults and for the treatment of generalized anxiety disorder in certain regions. Pregabalin acts by binding to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system, thereby modulating calcium influx and reducing the release of excitatory neurotransmitters such as glutamate, norepinephrine, and substance P. This mechanism helps to alleviate neuropathic pain and control seizure activity. Maglin 50 Capsule is administered orally, with dosing individualized based on the indication, patient response, and tolerability. Common adverse effects include dizziness, somnolence, dry mouth, edema, and weight gain, which generally diminish with continued use. Caution is advised in patients with renal impairment, and dose adjustments may be necessary. Pregabalin has potential for misuse and dependence; therefore, it should be prescribed and monitored carefully. Patients should avoid abrupt discontinuation to prevent withdrawal symptoms. Maglin 50 Capsule should be used under medical supervision to ensure safety and efficacy.